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Abstract 
 
Objective: The main objective of the study was to obtain the average LDL cholesterol level in Native 
Americans patients with Type II DM and cardiovascular disease who are receiving their healthcare at the 
Albuquerque Indian Health Service. Specifically, the study determined the percentage of patients meeting the 
Adult Treatment Panel III recommendations of an LDL <70 for high risk patients and the cost impact to lower 
the LDL in those not currently at this level. High risk being defined as having coronary heart disease.  
Design: The study design is a combination of a chart review and review of the Resource Patient Management 
Systems (RPMS) of patients receiving their healthcare at Albuquerque’s Indian Health Services hospital/clinics.  
Setting/population: The population is the Native American patients receiving their healthcare at the 
Albuquerque Indian Health Services and includes patients with both cardiovascular disease and Type II 
diabetes. The sample size consisted of 14 patients with Type II diabetes; age>18y/o; had seen the PCP at least 
once in the last three years; had at least 1 LDL value recorded in the past year, did not have abnormal liver 
enzymes/liver failure; did not have abnormal kidney function tests outside of normal limits; and did not have 
baseline LDL> 150mg/dl.  
Main outcome measures: The main outcome was to determine the average LDL levels of those who are 
considered “high risk” and to determine what proportion were treated to LDL<70 mg/dl. A secondary outcome 
assessed involved the average financial impact based upon projected attempts through lipid lowering agents to 
reach an LDL<70 mg/dl.  
Results: Twenty eight (28) percent of Albuquerque’s Indian Health Service “high risk” population is being 
treated to goal LDL levels. For those not currently achieving this level, Simvastatin ranging in dose from 2.5-80 
mg Q PM could be utilized to bring these patient to goal levels. Simvastatin is the first line agent utilized by the 
Albuquerque Indian Health Services. Based on the unit pricing of this particular statin, patients can be brought 
to goal at an average of $10 per year/per patient.  
Conclusion:  The conclusions of this particular research project are two fold. First in performing this research, it 
was found that only 28% Albuquerque’s Native American population who receive their care at the Albuquerque 
Indian Health Service were being treated to goal. Second, the additional cost to bring these patients to 
recommended LDL levels is not very large.  
 
Introduction  
Much research has been done in the areas of cardiovascular disease and diabetes and preventative measures that 
have been taken to combat these diseases. Recent data has shown that the mortality rate associated with 
cardiovascular disease has been declining since the 1970s in the many western countries. (2) Despite this 
decline is westernized countries, United States’ Native American populations are experiencing a gradual 
increase in mortality associated with cardiovascular disease.(1)  Although many factors many contribute to this 
discrepancy, including smoking, diet, and genetics a potential approach to this issue is stricter control of 
cholesterol levels. Recent recommendations by the National Cholesterol Education Program Report states that 
treating high risk patients to LDL levels to < 70 mg/dL is indeed beneficial. (3) Benefits to these patients being 
measured in terms the decrease of major cardiovascular events. The goal of this particular research was to 
attempt to find out what percentage of Albuquerque’s Indian Health Service cardiovascular disease and diabetic 
population were being treated to the recommended goal of <70mg/dl. After finding the percentage of patients 
that were actually being treated to goal, the next step would be to find out the additional cost needed to bring 
those patients to goal LDL levels.  
 
Methods 
Design:  The design is a combination of chart review of patients who seek services at the Albuquerque Indian 
Health Services and utilization of the data collection software used at the Albuquerque Indian Health Center, 
called the Resource Patient Management Systems (RPMS).   
Sample size:  The initial patient review consisted of 1000 patients to determine those who met the inclusion and 
exclusion criteria of the study.  The end sample size was 14. 
Inclusion criteria: diagnosis of Type II diabetes, 18 years or older; active patient(seen primary care provider at 
least once in the last three years) within the DMS database, a history of cardiovascular disease (having a 
documented myocardial infarction).  
Exclusion Criteria: abnormal liver enzymes (AST, ALT outside of normal Limits);  abnormal kidney function 
tests (GFR and creatinine levels outside of normal limits); baseline LDL> 150mg/dl. 
Methodology: 1000 patients were randomly selected from the above database. The charts were then randomly 
assigned values ranging from 1-1000.  The remaining charts were then subjected to the inclusion/exclusion 
criteria as described above. . The 14 remaining patient charts were then utilized to determine the data obtained 
in the results section. The patients’ LDL values, LDL values from goal and the percentage of LDL needed to be 
decreased in order to reach goal were obtained. Once the percentage of LDL needed to be decreased to reach 
goal LDL levels was obtained, the amount and cost of statin was obtained using the 2008-2009 Lexi-Comp’s 
Drug Reference Handbook. (5) Pricing per unit of drug was based on information obtain from the McKesson 
website. (6) The amount of medication to reach recommended LDL levels were then calculated for 1 day, 7 
days, 30 days, and 365 days. ( Ex. If a patient required an additional decrease in LDL of 33%, the additional 
amount of simvastatin to reach goal as recommended was 20 mg based upon information obtained using the 
Drug Reference Handbook. The amount per unit was found to be $ .02, which was based on the price per unit as 
found on the McKesson website. This amount was multiplied by 1, 7, 30, 365 days to the total cost to bring the 
patient to goal LDL level. Once this level was obtained for each individual, the values were averaged for the 
study individuals. )   
 
Statistical/Data Analysis: Confidence intervals obtained were based on information obtained from Scientific 
Calculations. (7) 
 
Results 
The final sample size of participants included in the final portion of the study was 14.  Only 28 percent (95% CI 
2-42) of the patients who met the study criteria were being treated to a goal LDL of less than 70 mg/dl. See 
Figure 1.    
The percentage of LDL required to reach the recommend goal of <70 mg/dl was calculated for each patient. The 
average LDL percentage needed to reach goal levels ranged between 13-50%. The LDL percentages were then 
utilized to determine which medications would be best suited to lower the patients LDL to the recommend level 
based on the info obtained from the Drug Information Handbook. Based on the information obtained from the 
Drug Information Handbook, it was found that simvastatin ranging from 2.5 to 80 mg could be utilized to bring 
this particular subset of patient to goal levels. Based on the amount of drug needed to bring this subset of 
patients to recommended level, the average cost of additional drug to bring patients to goal level was calculated 
for 1 day, 1 week, 1 month and 1 year. Based on the percentage LDL reduction to reach goal levels and the per 
unit pricing the average additional cost to bring these diabetic patients to goal averages $10 a year per patient.  
These results can be seen on Figure 1.  
 
Discussion 
1)  In performing this research it was found that only 28% of the diabetic patients who receive their 
care at the Albuquerque Indian Health Service were being treated to recommend goal LDL levels. 
This percentage is very surprising considering that diabetes and cardiovascular disease is on the rise 
among the Native American Community. What is even more surprising is that the additional cost, 
based on unit pricing, could be as low as $10 person per year based on McKesson pricing which is 
utilized by the Indian Health Service.  
2) Despite being at a higher risk of for developing diabetes and the subsequent complications, a lower 
percentage of the Albuquerque Native American population is being treated to LDL recommendation 
as compared to the rest of the United States. According to Kennedy et al, 42% of United States’ 
general diabetic population is being treated to goal LDL level.(4) Although the complications of 
diabetes are due to multiple variables, perhaps it would be justifiable to attempt to treat these high 
risk patients to levels comparable LDL levels of the national average.  By simply reducing the LDL 
level to reach the national level, one is likely to see a reduction in mortality of the Native American 
Populations.  
3) In performing this particular research attempt it is important to reiterate that diabetes and its 
complications are multi-factorial. It would also be important to note that many factors that affect the 
mortality of diabetic patients were not controlled for in this particular study. Factors that were not 
controlled that are worthy for consideration include genetics, smoking, diet, weight, previous medical 
problems, etc, all factors that could affect the mortality of diabetic patients.  
4) Based on searches of the Native Health, Pub Med, Medline plus, and Cochrane databases research 
related to the area of diabetes, Indian Health Service, LDL goal levels, and mortality, no research has 
been performed specific to this area. Further research should be performed in order to determine if 
the obtained LDL percentage remains consistent. Further research should include a larger scale study 
with a greater number of patients. Further studies including other Indian Health Service Units might 
add further insight into the issue at hand. In addition, greater care should be taken to control for 
factors including smoking, genetics, other medical problems, etc, all factors that could complicate 
study outcomes.  
Strengths and limitations  
Strengths of this particular study include that it was the first chart review at the Albuquerque Indian Health 
Services that served to evaluate treatment goals of LDL levels. 
Limitations of this particular study includes the total number of participates, after inclusion and exclusion 
criteria, resulting in a rather wide confidence interval. Other potential limitations of this study are since the 
study was done using patients who sought treatment at the Albuquerque Indian Health Services the results can 
not be generalized to the non Native American populations. In addition, the data obtained were of patients who 
visited Albuquerque’s Indian Health Service so the results can not be generalized to include other Indian Health 
Service facilities. This particular research attempt was a very good pilot study with much room for additional 
research. Additional research should include a much larger chart review that will lead to more data for analysis. 
The greater amount of study participants will lead to a narrowing of the confidence interval and thus lead more 
accurate conclusion.  
Another limitation of this study was the assumption that simvastatin could be utilized to reach goal LDL levels, 
when in reality patients often have different responses to different medications.  Simvastatin was chosen for this 
particular study based on the IHS formulary. In addition, many patients often require multiple treatment 
modalities that include other cholesterol lowering medications and diet and lifestyle changes that could affect 
LDL levels.  In addition, LDL levels obtained were based on isolated LDL levels and no information regarding 
previous treatment attempts, including medications and diet and exercise regimens,  were obtained.  
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Figures 
Figure 1 
Pt LDL mg/dl 
% LDL 
reduction   Recommended statin % LDL Decrease (3) 
Unit 
Cost  Cost  Cost Cost Cost 
    to goal and dosage     (1 day) (1Week) 
(1 
Month) (1 year) 
1 59 at goal  
no additional therapy 
needed 0 0 0 0 0 0 
2 133.6 50 
80 mg of simvastatin po 
Qpm -47% 0.08 0.08 0.56 2.4 29.2 
3 89 21 
5 mg of simvastatin po 
Qpm  -26% 0.02 0.02 0.14 0.6 7.3 
4 130 46 
80 mg of simvastatin po 
Qpm  -47% 0.08 0.08 0.56 2.4 29.2 
5 80.2 13 
2.5 mg of simvastatin po 
Qpm  -13% 0.02 0.02 0.14 0.6 7.3 
6 83 16 
2.5 mg of simvastatin po 
Qpm  -13% 0.02 0.02 0.14 0.6 7.3 
7 125 44 
80 mg of simvastatin po 
Qpm  -47% 0.08 0.08 0.56 2.4 29.2 
8 80 13 
2.5 mg of simvastatin po 
Qpm  -13% 0.02 0.02 0.14 0.6 7.3 
9 70 at goal  
no additional therapy 
needed 0 0   0 0 0 
1
0 105.6 33 
40 mg of simvastatin po 
Qpm  -41% 0.05 0.05 0.35 1.5 18.5 
1
1 87.6 20 
5 mg of simvastatin po 
Qpm  -26% 0.02 0.02 0.14 0.6 7.3 
1
2 94.6 26 
5 mg of simvastatin po 
Qpm  -26% 0.02 0.02 0.14 0.6 7.3 
1
3 73.4 at goal  
no additional therapy 
needed 0 0 0 0 0 0 
1
4 53.6 at goal  
no additional therapy 
needed 0 0 0 0 0 0 
                    
 Average  
LDL 
(mg/dl)   
Ave. % LDL 
Decrease Ave Unit 
Ave 
cost  
Ave 
Cost 
Ave 
Cost 
Ave 
cost 
 90.34     cost (1day) (1 week) 
(1 
Month) (1 year) 
    20.42% $0.03 $0.03  $0.21 $0.87 $10.70 
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